GPNMB, Aviva Systems Biology, ARP44501

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human GPNMB and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 20 commercial research antibodies against human GPNMB.

The collection of antibodies was tested using U-87 MG WT and GPNMB KD cells in the applications WB (WT and KD cell lysates/60 µg protein), IP (WT cell lysate) and IF (WT and KD cells) according to YCharOS standard protocols (see reference). siRNA technology was used to knockdown (KD) the target gene.

In WB (1:500 Antibody dilution) ARP44501 detected multiple bands of both higher and lower molecular weight than predicated bands size – 64 kDa, in lysates from both genotypes. No band was detected following IP (2 µg Ab used). In IF (1:250 antibody dilution) comparable staining intensities were observed in both KD and WT cells.

We highly encourage other scientists to share their observations.